# Observational adenocarcinoma studies recruiting: 31 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 31 trials that are observational for adenocarcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting observational adenocarcinoma studies: 31 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/observational/adenocarcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 31
- Recruiting or not yet: 31
- Read on: November 19, 2026

## Trials

The 25 newest of 31, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 5, 2026 | NCT07858500 | Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE) | Astellas Pharma Europe Ltd. | Observational | Not yet recruiting | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable... | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858500) |
| October 5, 2026 | NCT07858097 | Bethesda Classification and Risk Stratification in Differentiated Thyroid Carcinoma | Assiut University | Observational | Not yet recruiting | Differentiated Thyroid Carcinoma, Papillary Thyroid Carcinoma, Follicular Thyroid Carcinoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858097) |
| October 2, 2026 | NCT07856017 | Development of an Intraoperative Adaptive Biopsy System for Prostate Cancer: Integrating Imaging Navigation With Metabolic Feedback for... | Shanghai Zhongshan Hospital | Observational | Recruiting | Prostate Cancer (Adenocarcinoma), Prostate Cancer (Diagnosis) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856017) |
| September 2, 2026 | NCT07800754 | A Study in Greece Observing How Patients With Stomach and Esophageal Cancer Are Diagnosed and Treated in Everyday Medical Practice | AstraZeneca | Observational | Recruiting | Gastric Cancer, Gastroesophageal Junction Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07800754) |
| August 24, 2026 | NCT07781137 | Analysis of Long-term Outcomes of Endoscopic Resection of Duodenal and Ampullary Mucosal and Submucosal Lesions | Western Sydney Local Health District | Observational | Recruiting | Duodenal Adenoma, Duodenal Carcinoma, Papillary Adenoma, Papillary Adenocarcinoma, Endoscopic Mucosal Resection | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781137) |
| August 21, 2026 | NCT07780305 | ABCSG R07 Rectal Cancer Registry | Austrian Breast & Colorectal Cancer Study Group | Observational | Recruiting | Rectal Cancer, Adenocarcinoma of Rectum | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780305) |
| August 17, 2026 | NCT07769346 | The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry | Appendix Cancer Pseudomyxoma Peritonei Research Foundation | Observational | Recruiting | Appendix Cancer, Pseudomyxoma Peritonei | 10,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07769346) |
| May 14, 2026 | NCT07587268 | Molecular Profiling for Risk Stratification in Appendiceal Cancer | City of Hope Medical Center | Observational | Recruiting | Appendiceal Cancer, Appendiceal Adenocarcinoma | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07587268) |
| April 8, 2026 | NCT07516886 | Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy | Lithuanian University of Health Sciences | Observational | Recruiting | Prostate Cancer (Post Prostatectomy), Prostate Cancer (Adenocarcinoma), Prostate Cancer (Diagnosis), Prostate Specific... | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516886) |
| March 20, 2026 | NCT07484971 | Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria | Société Algérienne de Formation et Recherche en Oncologie | Observational | Recruiting | Prostate Cancer, Prostate Cancer (Diagnosis), Prostate Cancer (Post Prostatectomy), Prostate Cancer Patients Treated by... | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07484971) |
| March 10, 2026 | NCT07460726 | PRIAPUS-PCa Study: Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) Impact on Sexual Function on Men With... | CancerCare Manitoba | Observational | Not yet recruiting | Prostate Cancer (Adenocarcinoma), Erectile Abnormalities, Sexual Dysfunction Male | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07460726) |
| February 12, 2026 | NCT07407608 | ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0 | University of Milano Bicocca | Observational | Recruiting | Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Non-Metastatic | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407608) |
| January 27, 2026 | NCT07370597 | LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy. | Jules Bordet Institute | Observational | Recruiting | Prostate Cancer (Adenocarcinoma) | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07370597) |
| August 15, 2025 | NCT07124000 | DESTINY-PANTUMOUR04 | AstraZeneca | Observational | Recruiting | Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07124000) |
| July 2, 2025 | NCT07047495 | Personalization of External Beam Radiation Therapy in Localised Tumours | European Institute of Oncology | Observational | Recruiting | Breast Adenocarcinoma, Prostate Cancer (Adenocarcinoma) | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07047495) |
| May 30, 2025 | NCT06996249 | Prospective Data Collection Initiative on Thoracic Malignancies | Dutch Society of Physicians for Pulmonology and Tuberculosis | Observational | Recruiting | Lung Cancer, Thoracic Cancer, Lung Cancer, Nonsmall Cell, Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Lung... | 12,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06996249) |
| March 30, 2025 | NCT06902545 | A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer. | Astellas Pharma Korea, Inc. | Observational | Recruiting | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable... | 377 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06902545) |
| March 10, 2025 | NCT06867172 | Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma | Carol Davila University of Medicine and Pharmacy | Observational | Recruiting | Pancreatic Steatosis, Pancreatic Cyst, Pancreatic Adenocarcinoma | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06867172) |
| March 6, 2025 | NCT06862856 | Flotufolastat F 18 PET in Men With Very Low PSA Recurrence | Massachusetts General Hospital | Observational | Recruiting | Prostate Cancer (Adenocarcinoma), Prostate Specific Antigen | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06862856) |
| February 20, 2025 | NCT06838520 | Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer | The First Affiliated Hospital with Nanjing Medical University | Observational | Not yet recruiting | Prostate Cancer (Adenocarcinoma) | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06838520) |
| February 19, 2025 | NCT06834152 | Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer | University of Zurich | Observational | Recruiting | Localized Prostate Carcinoma, Prostate Cancer (Adenocarcinoma), Prostate Hyperplasia, Lower Urinary Track Symptoms | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06834152) |
| February 11, 2025 | NCT06820333 | Impact of \[18F\] PSMA-1007 Imaging for Primary Staging of Prostate Cancer | Heinrich-Heine University, Duesseldorf | Observational | Recruiting | Prostate Cancer (Adenocarcinoma) | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06820333) |
| September 20, 2024 | NCT06605404 | Pan-tumor MRD Study | Paradigm Health | Observational | Recruiting | Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer, Gastric and Gastroesophageal Junction (GEJ)... | 1,350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06605404) |
| March 29, 2024 | NCT06337760 | YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs. | European Institute of Oncology | Observational | Recruiting | Neuroendocrine Neoplasm, Adenocarcinoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06337760) |
| November 13, 2023 | NCT06128343 | Anatomical-Clinical Base of Adenocarcinoma Pancreatic | University Hospital, Toulouse | Observational | Recruiting | Adenocarcinoma, Carcinoma, Neoplasms | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06128343) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| European Institute of Oncology | 2 |
| Assiut University | 1 |
| Paradigm Health | 1 |
| Jules Bordet Institute | 1 |
| Institute of Cancer Research, United Kingdom | 1 |
| Dutch Society of Physicians for Pulmonology and Tuberculosis | 1 |
| Appendix Cancer Pseudomyxoma Peritonei Research Foundation | 1 |
| Western Sydney Local Health District | 1 |
| Austrian Breast & Colorectal Cancer Study Group | 1 |
| Northwestern University | 1 |
| Société Algérienne de Formation et Recherche en Oncologie | 1 |
| Shanghai Zhongshan Hospital | 1 |
| Centre Hospitalier Universitaire de Saint Etienne | 1 |
| Carol Davila University of Medicine and Pharmacy | 1 |
| University Hospital, Toulouse | 1 |
| City of Hope Medical Center | 1 |
| University of Zurich | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| CancerCare Manitoba | 1 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1 |
| Massachusetts General Hospital | 1 |
| Astellas Pharma Korea, Inc. | 1 |
| University of Milano Bicocca | 1 |
| Heinrich-Heine University, Duesseldorf | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 9 |
| Italy | 3 |
| China | 2 |
| France | 2 |
| Germany | 2 |
| Canada | 2 |
| Belgium | 1 |
| United Kingdom | 1 |
| Netherlands | 1 |
| Australia | 1 |
| Austria | 1 |
| Greece | 1 |
| Algeria | 1 |
| Romania | 1 |
| Switzerland | 1 |
| South Korea | 1 |
| Lithuania | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Russian restaurants in the United States](https://specstream.ai/data/businesses/russian-restaurants/united-states)
- [Handyman services in the United States](https://specstream.ai/data/businesses/handyman-services/united-states)
- [B2B mining companies in the United States](https://specstream.ai/data/businesses/b2b-mining-companies/united-states)
- [Podiatrists in the United States](https://specstream.ai/data/businesses/podiatrists/united-states)
- [Farm equipment suppliers in the United States](https://specstream.ai/data/businesses/farm-equipment-suppliers/united-states)
- [Acupuncture clinics in the United States](https://specstream.ai/data/businesses/acupuncture-clinics/united-states)
